Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. Mai 2018 08:30 ET | Quelle: Veru Inc.

Veru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting

MIAMI, May 17, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced the publication of data from preclinical studies of VERU-111, a...
17. Mai 2018 08:15 ET | Quelle: Veru Inc.

Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual Meeting

MIAMI , May 17, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a urology and oncology biopharmaceutical company, today announced the publication of data from preclinical studies of VERU-111, a...
09. Mai 2018 06:30 ET | Quelle: Veru Inc.

Veru Reports Fiscal 2018 Second-Quarter Financial Results

-- Promising Oncology Drug Data to be Presented at Upcoming American Urological Association Medical Conference; FDA Waives Drug Application Fee; BE Clinical Studies Results Anticipated for Drugs in...
03. Mai 2018 08:40 ET | Quelle: Veru Inc.

Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association Meeting

MIAMI, May 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that data from a pre-clinical study of VERU-111, a novel oral alpha...
03. Mai 2018 08:30 ET | Quelle: Veru Inc.

Veru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9th

MIAMI, May 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that on May 9, 2018, the company will report financial results for...
22. März 2018 08:30 ET | Quelle: Veru Inc.

FDA Grants Fee Waiver for Tamsulosin DRS New Drug Application

MIAMI, March 22, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on urology and oncology, announced that the U.S. Food and Drug Administration (FDA) granted its...
16. März 2018 08:30 ET | Quelle: Veru Inc.

Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Annual EAU Congress

MIAMI, March 16, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on urology and oncology, announced that data from a preclinical study of VERU-111, a novel oral...
14. März 2018 08:30 ET | Quelle: Veru Inc.

Veru to Present at the Oppenheimer 28th Annual Healthcare Conference on March 21, 2018

MIAMI, March 14, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced that that the company will present at the Oppenheimer 28th Annual Healthcare Conference at 1:35 p.m. ET on...
05. März 2018 08:30 ET | Quelle: Veru Inc.

Veru Completes $10 Million Synthetic Royalty Financing on FC2 Business

MIAMI, March 05, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced that it has completed a $10 million “synthetic” royalty financing on FC2 Female Condom® product sales with SWK...
14. Februar 2018 06:30 ET | Quelle: Veru Inc.

Veru Reports Fiscal 2018 First-Quarter Financial Results

-- Company Advancing Multiple Drugs from Pipeline; First New Drug Application (NDA) Remains on Track for Submission in 2018; Two Additional NDAs Expected to be Filed in 2019; Promising Oncology Drug...

Vorherige Seite

Nächste Seite